These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23032745)

  • 1. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
    Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
    Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
    Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
    Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
    J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
    Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
    Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
    Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
    Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
    Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
    Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
    Diefenbach CS; Gnjatic S; Sabbatini P; Aghajanian C; Hensley ML; Spriggs DR; Iasonos A; Lee H; Dupont B; Pezzulli S; Jungbluth AA; Old LJ; Dupont J
    Clin Cancer Res; 2008 May; 14(9):2740-8. PubMed ID: 18451240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
    Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
    Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
    Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
    Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
    Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
    J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
    Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
    Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.
    Okada H; Butterfield LH; Hamilton RL; Hoji A; Sakaki M; Ahn BJ; Kohanbash G; Drappatz J; Engh J; Amankulor N; Lively MO; Chan MD; Salazar AM; Shaw EG; Potter DM; Lieberman FS
    Clin Cancer Res; 2015 Jan; 21(2):286-94. PubMed ID: 25424847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
    Takeoka T; Nagase H; Kurose K; Ohue Y; Yamasaki M; Takiguchi S; Sato E; Isobe M; Kanazawa T; Matsumoto M; Iwahori K; Kawashima A; Morimoto-Okazawa A; Nishikawa H; Oka M; Pan L; Venhaus R; Nakayama E; Mori M; Doki Y; Wada H
    J Immunother; 2017 May; 40(4):140-147. PubMed ID: 28338507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
    Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
    Legat A; Maby-El Hajjami H; Baumgaertner P; Cagnon L; Abed Maillard S; Geldhof C; Iancu EM; Lebon L; Guillaume P; Dojcinovic D; Michielin O; Romano E; Berthod G; Rimoldi D; Triebel F; Luescher I; Rufer N; Speiser DE
    Clin Cancer Res; 2016 Mar; 22(6):1330-40. PubMed ID: 26500235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
    Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
    J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.